Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.1252W HIGH $47.65
Volume
294.48 K
Value Traded
23.38 M
Short % Float
12.83%
Days to Cover
5.2
-2.15%Week
-20.13%1 Month
-24.77%3 Month
-24.16%6 Month
+41.47%5 Year
+41.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.81 B
EPS (TTM)
-3.95
P/E Ratio
-
Ent. Value
1.14 B
Total Shares
88.41 M
Float Shares
60.84 M
Insiders
31.19%
Institutions
89.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MLYS Catalyst Timeline
Dated clinical, regulatory and corporate events for Mineralys Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mineralys Therapeutics, Inc.
193Total events
8Upcoming
46Tier-1 (high impact)
2022 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationlorundrostatFiledPresentation
Lorundrostat CKD subgroup data presented orally at ASN Kidney Week 2026
hypertension and chronic kidney diseasesource ↗
▲Subgroup AnalysislorundrostatFiledClinical Data
Launch-HTN CKD subgroup analysis: SBP reductions and 52% UACR reduction
hypertension with chronic kidney diseasesource ↗
●Management ChangeCorporate
Kristine Peterson and Lonnel Coats appointed to Board of Directors
▲Topline ReadoutlorundrostatFiledClinical Data
Launch-HTN Week 12 analysis: 46% achieved AHA/ACC SBP target <130 mmHg
difficult-to-treat hypertensionsource ↗
▲Oral PresentationlorundrostatFiledPresentation
New Launch-HTN analysis presented at AHA-HTN 2026: 46% achieved SBP <130 mmHg at Week 12
difficult-to-treat hypertensionsource ↗
▲Full ResultslorundrostatFiledClinical Data
Final results of Phase 2 Explore-OSA trial of lorundrostat
obstructive sleep apnea and hypertensionsource ↗
▲Safety Data UpdatelorundrostatFiledClinical Data
Explore-OSA safety data: favorable profile, no evidence of significant safety events including hyperkalemia
obstructive sleep apnea and hypertensionsource ↗
▲Secondary Endpoint DatalorundrostatFiledClinical Data
Explore-OSA secondary endpoint: 11.1 mmHg morning SBP reduction at Week 4
obstructive sleep apnea and hypertensionsource ↗
▲Oral PresentationlorundrostatFiledPresentation
Final Explore-OSA results presented at AHA Hypertension Scientific Sessions 2026
obstructive sleep apnea with hypertensionsource ↗
▲Additional DatalorundrostatFiledClinical Data
New Week 12 analysis from pivotal Launch-HTN trial
difficult-to-treat hypertensionsource ↗
▲Full ResultslorundrostatFiledClinical Data
Final results of Phase 2 Explore-OSA trial of lorundrostat
obstructive sleep apnea with hypertensionsource ↗
◆Poster PresentationlorundrostatFiledPresentation
Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants with Uncontrolled Hypertension (SUN-257) at ENDO 2026
uncontrolled hypertensionsource ↗
◆Oral PresentationPresentation
Mineralys Therapeutics to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Mineralys Therapeutics corporate presentation at Jefferies Global Healthcare Conference
▲Partnership / LicenselorundrostatFiledCorporate
Repurchase of lorundrostat royalty obligation from Tanabe for $200M upfront and up to $100M milestones
▲Debt Royalty FinancingCorporate
Entered into $500M senior secured term loan facility with Pharmakon Advisors
▲Partnership / LicenselorundrostatFiledCorporate
Amended Tanabe license agreement to eliminate royalty obligations
◆Oral PresentationlorundrostatFiledPresentation
New data from Phase 3 Launch-HTN trial presented at ESH 2026
hypertension and chronic kidney diseasesource ↗
◆Oral PresentationPresentation
Mineralys Therapeutics Fireside Chat at Bank of America Securities Health Care Conference
▲FDA Filing AcceptedlorundrostatFiledRegulatory Filing
FDA accepted NDA for lorundrostat in adults with hypertension
hypertensionsource ↗
▲FDA Filing AcceptedlorundrostatFiledRegulatory Filing
FDA accepted NDA for lorundrostat in adults with hypertension
hypertensionsource ↗
▲FDA Filing AcceptedlorundrostatFiledRegulatory Filing
FDA accepted NDA for lorundrostat for hypertension
hypertensionsource ↗
▼Topline ReadoutlorundrostatFiledClinical Data
Topline results from Explore-OSA trial: AHI primary endpoint not met, but BP reduction observed
obstructive sleep apnea and hypertensionsource ↗
◆Topline ReadoutlorundrostatFiledClinical Data
Topline results from EXPLORE-OSA trial anticipated
obstructive sleep apnea and hypertensionsource ↗
▲Enrollment CompletelorundrostatFiledTrial
Enrollment completed in Explore-OSA trial
hypertension and moderate-to-severe obstructive sleep apneasource ↗
●Trial InitiationlorundrostatFiledTrial
Transform-HTN open-label extension trial ongoing
uncontrolled or treatment-resistant hypertensionsource ↗
◆Topline ReadoutlorundrostatFiledClinical Data
Topline data from Launch-HTN trial
uHTN or rHTNsource ↗
▲Enrollment CompletelorundrostatFiledTrial
Completed enrollment in Explore-OSA trial
obstructive sleep apneasource ↗
◆Late-BreakerlorundrostatFiledPresentation
Late-breaking presentation of Phase 2 Explore-CKD trial results at ASN Kidney Week 2025
hypertension and comorbid chronic kidney diseasesource ↗
◆Oral PresentationlorundrostatFiledPresentation
Launch-HTN trial featured at ASN Kidney Week 'Best of JAMA and NEJM' program
uncontrolled hypertension and treatment resistant hypertensionsource ↗
▲Primary Endpoint MetlorundrostatFiledClinical Data
Explore-CKD met primary endpoint: reduction in AOSBP at week 4
chronic kidney disease and hypertensionsource ↗
▲Secondary Endpoint DatalorundrostatFiledClinical Data
Explore-CKD showed 25.6% placebo-adjusted reduction in UACR at week 4
chronic kidney disease and hypertensionsource ↗
▲Enrollment CompletelorundrostatFiledTrial
Enrollment completed in Explore-OSA trial
hypertension and moderate-to-severe obstructive sleep apneasource ↗
Past FDA Catalysts and PDUFA Decisions
How MLYS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-21 | lorundrostat | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 22%
Micro Cap(rank 145 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| lorundrostat Small moleculeNCT05968430 | Hypertension | NDA/BLA | ACTIVE NOT_RECRUITING | 2,444 | May 1, 2027 | ||||||
| lorundrostat Small moleculeCompletedNCT06785454 | Obstructive Sleep Apnea | Phase 2 | COMPLETED | 48 | Dec 29, 2025 | ||||||
| MLS-101 Small moleculeCompletedNCT05001945 | Hypertension, Renal | NDA/BLA | COMPLETED | 200 | Oct 7, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every MLYS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lorundrostat | hypertension and chronic kidney disease | Phase 3 | 2026-10-22 | systolic blood pressure reduction ckd: 9.6 mmHg; systolic blood pressure reduction non ckd: 12.2 mmHg; target sbp below 130mm Hg ckd: 44%; target sbp below 130mm Hg non ckd: 48%; albuminuria reduction: 52.2%Read More | Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Congleton JonDirector, Officer (Chief Executive Officer) | Sell | -75,000 528,621 held | $25.46 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MLYS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.8 % (-18.2 %) | 207.55 M | 7.69 M |
MLYS Institutional Ownership Trends
MLYS Short Interest
Shares sold short, counted twice a month.
12.83%
Short % of Float
of tradable shares sold short
7.8M
Shares Sold Short
-15.0% vs prior count
5.2 High
Days to Cover
trading days of normal volume to buy every short share back
1.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MLYS ranks across every disease it competes in
Competitive Position is a premium feature
See how MLYS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMLYS News
MLYS▼ -0.6%today
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics presented new data on lorundrostat at ASN Kidney Week 2026. The Phase 3 Launch-HTN trial demonstrated significant reductions in systolic blood pressure for participants with and without chronic kidney disease (CKD). Additionally, lorundrostat reduced albuminuria by 52% in CKD patients, supporting its efficacy and safety profile.
Read more →MLYSMineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics has appointed Kristine Peterson and Lonnel Coats to its Board of Directors. Both bring extensive experience in launching and commercializing therapies, particularly in cardiovascular and metabolic diseases. Their appointments come as the company prepares for the potential approval and launch of lorundrostat, aimed at treating uncontrolled hypertension.
Read more →MLYSMineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics presented new data on lorundrostat at the AHA Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension reached the recommended systolic blood pressure target at 12 weeks. The Explore-OSA trial also showed meaningful reductions in morning blood pressure without affecting apnea-hypopnea indices, highlighting lorundrostat's potential for treating hypertension and related conditions.
Read more →MLYSMineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Mineralys Therapeutics announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026. The trial focuses on patients with uncontrolled hypertension despite multiple antihypertensive medications. Lorundrostat is an investigational drug aimed at addressing hypertension and related conditions, showing a favorable safety profile in previous studies.
Read more →MLYSMineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics announced the presentation of five abstracts related to lorundrostat at the AHA Hypertension Scientific Sessions 2026. The drug is being developed for uncontrolled hypertension and related comorbidities, showing efficacy in clinical trials. The company emphasizes the importance of addressing hypertension, a leading cause of death in the U.S.
Read more →MLYSMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics has announced the granting of inducement stock options and restricted stock units to two new non-executive employees. This decision, made by the Compensation Committee, is part of the company's strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). The awards will vest over a four-year period, aligning with the company's focus on developing treatments for hypertension and related conditions.
Read more →MLYSMineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Mineralys Therapeutics will participate in the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026. The company focuses on developing treatments for hypertension and related comorbidities. Their investigational product candidate, lorundrostat, is a selective aldosterone synthase inhibitor. A live webcast of the event will be available on their website.
Read more →MLYSMineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Mineralys Therapeutics announced that new data from the Transform-HTN trial of lorundrostat will be presented at the American Heart Association Scientific Sessions 2026. This trial assesses the long-term safety and efficacy of the aldosterone synthase inhibitor in patients with hypertension. The data highlights the potential benefits of lorundrostat in managing hypertension and related comorbidities.
Read more →MLYSMineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Mineralys Therapeutics, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference from September 8-10, 2026. The company focuses on developing treatments for hypertension and related conditions. A live webcast of the event will be available on their website, showcasing their commitment to transparency and investor relations.
Read more →MLYSMineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics has granted inducement stock options and restricted stock units to Dr. Terry Ferguson, its new Chief Medical Officer. The awards, totaling 135,000 shares in options and 102,400 shares in restricted stock, are part of the company's 2025 Employment Inducement Incentive Award Plan. The vesting of these awards is contingent upon continued service over a four-year period.
Read more →MLYSMineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics reported its second quarter 2026 financial results, highlighting a PDUFA target date of December 22, 2026, for lorundrostat. The company appointed Dr. Terry Ferguson as Chief Medical Officer to lead its medical activities. Despite a significant net loss of $241.1 million, Mineralys strengthened its financial position through strategic financing initiatives. Preparations for the commercial launch of lorundrostat are progressing well.
Read more →MLYSMineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
Mineralys Therapeutics, a biopharmaceutical company, will announce its second quarter 2026 financial results on August 11, 2026. The company is focused on developing treatments for hypertension and related comorbidities. A live webcast of the conference call will be available on their website.
Read more →MLYSMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics presented late-breaking data at ENDO 2026, showing that lorundrostat significantly reduces heart failure risk biomarkers in patients with uncontrolled hypertension. The analysis from the Launch-HTN and Advance-HTN trials indicates that lorundrostat may positively influence pathways involved in heart failure. The drug is currently under FDA review, with a target decision date set for December 22, 2026.
Read more →MLYS▼ -5%on this news
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics, a biopharmaceutical company, will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026. The event will take place in Miami, and a live webcast of the fireside chat will be available on their website. Mineralys focuses on developing treatments for hypertension and related comorbidities.
Read more →MLYS▼ -5%on this news
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics announced that late-breaking data from their clinical trials of lorundrostat will be presented at the Endocrine Society's annual meeting, ENDO 2026. The poster presentation will showcase findings regarding the drug's ability to modulate heart failure risk biomarkers in participants with uncontrolled hypertension. This investigational therapy targets dysregulated aldosterone levels, a major contributor to hypertension. The presentation reflects confidence in lorundrostat's efficacy and safety based on completed late-stage clinical trials.
Read more →MLYS▼ -13.1%on this newsshared move
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys Therapeutics has announced the repurchase of its royalty obligations related to lorundrostat from Tanabe Pharma for $200 million upfront and up to $100 million based on future milestones. Concurrently, the company secured a $500 million senior secured term loan and priced a $150 million common stock offering. These moves are expected to enhance Mineralys' financial position and operational flexibility.
Read more →MLYS▼ -13.1%on this newsshared move
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics has announced the pricing of an underwritten offering of 5,660,378 shares at $26.50 each, aiming to raise approximately $150 million. The proceeds will be used to fund a $200 million upfront payment for repurchasing a royalty obligation. The offering is expected to close on June 4, 2026, pending customary conditions.
Read more →About Mineralys Therapeutics, Inc.
Headquarters150 N. RADNOR CHESTER ROAD, RADNOR, PA
BIOPHARMAWATCH ELITE PLUS
Trade the next MLYS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime